Essentials
• Natural antibodies to oxidation-specific epitopes have antithrombotic properties.
• We evaluated the relation between natural IgM and IgG antibodies and the venous thrombosis risk.
• Risk of recurrent thrombosis was higher in patients with low natural IgM antibody levels.
• The protective effect of high IgM levels suggests a role of innate immune response in thrombosis.
Summary. Background and objectives: Natural antibodies to oxidation-specific epitopes protect from atherothrombotic events. Whether mechanisms of innate immunity are relevant in the pathogenesis of venous thromboembolism (VTE) is unknown. Patients/Methods: We measured plasma levels of immunoglobulin M (IgM) antibodies to oxidized low-density lipoproteins (OxLDL) and phosphocholine (PC) by enzyme linked immune assay in 663 patients with unprovoked VTE, who were prospectively followed after discontinuation of anticoagulation for a median of 8.8 years. The study endpoint was recurrent VTE. Results: IgM antibody levels to OxLDL and PC were higher in patients without compared to those with recurrent VTE (n = 174, 26.2%). For each doubling of OxLDL-IgM or PC-IgM the hazard ratio (HR) of recurrence was 0.88 (95% confidence interval [CI], 0.77-1.01) and 0.82 (95% CI, 0.71-0.94), respectively. After 5 years the probability of recurrence in patients with
Introduction
Thromboembolic cardiovascular disease is frequent in the general population and remains the leading cause of death in resourced countries [1] . The key element in the pathogenesis of arterial thrombosis is atherosclerotic transformation of the vessel wall that starts with the deposition, retention and consecutive oxidation of low-density lipoproteins (LDL) [2] . This process triggers inflammatory and immune responses that are characterized by the recruitment of monocyte-derived macrophages, which take up oxidized (Ox)LDL, and involvement of many other cell types [2] .
Not only mechanisms of cellular but also those of innate immunity operate during atherogenesis and exert disease modulatory effects [3] . These include natural antibodies, which are pre-existing without infection or specific immune exposure and bind to neo-self-structures induced during processes of oxidative stress or apoptosis [4] . These antibodies, which are primarily of the immunoglobulin M (IgM) class, recognize oxidation-specific epitopes (OSE) on OxLDL and inhibit prothrombotic properties of OxLDL [5, 6] . Autoantibodies against OxLDL were found in atherosclerotic lesions and human blood [3] . In patients undergoing coronary angiography, OxLDL-specific IgM antibody levels were inversely correlated with coronary artery disease, whereas OxLDL-specific immunoglobulin G (IgG) antibodies were correlated positively [7] . In a prospective population-based study, low antiOxLDL IgM antibodies predicted the outcome of cardiovascular disease independent of classical risk factors [8] . A subset of OxLDL-specific IgMs bind phosphocholine (PC) of oxidized phospholipids and these IgMs have been suggested to mediate many of the protective effects of anti-OxLDL IgM [6] .
The pathogenesis of arterial and venous thromboembolism (VTE) is intertwined as the two share several risk factors [9] . In particular, VTE is associated with proinflammatory states, including dyslipoproteinemia or obesity, as reflected by higher C-reactive protein levels [10] [11] [12] . In mice deep vein thrombosis (DVT) starts as sterile inflammation with massive recruitment of neutrophils and monocytes, followed by platelet interaction and tissue factor exposure [13] .
Following-up on these findings we hypothesized that higher plasma levels of OSE-specific natural IgM antibodies are associated with a lower risk of recurrent VTE.
Methods

Antibody determination
IgM and IgG antibody levels to OxLDL and PC were determined by chemiluminescent ELISA in the plasma of venous blood drawn 3 weeks after discontinuation of anticoagulation from 663 patients (median age 47 years [25th, 75th percentiles 37, 59], 54% women, body mass index 26.4 kg m À2 [23.5, 29 .7]) with unprovoked DVT or pulmonary embolism. Patients were prospectively followed for a median of 8.8 years (5, 12) after having stopped oral anticoagulation [14] . The study endpoint was objectively confirmed recurrent VTE. As previously described [15] , microtiter plates were coated with copper-oxidized LDL prepared by incubation of LDL with Cu2 + SO4 and PC-BSA (Biosearch Technologies, Novato, CA, USA). Fifty lL of diluted plasma were added and incubated overnight. Antibody binding was detected with an alkaline phosphatase-conjugated goat anti-human IgM (A3437; Sigma Aldrich, St. Louis, MO, USA) or goat anti-human IgG (A8542, Sigma Aldrich). After incubation, 25 lL of a 30% LumiPhos Plus solution in dH20 (Lumigen Inc., Southfield, MI, USA) were added. The light emission was measured on a WALLAC VIKTOR II luminometer (Perkin Elmer, Waltham, MA, USA) and expressed as relative light units (RLU) per 100 ms. The study was approved by the ethics committee of the Medical University of Vienna.
Statistical analyses
Continuous variables are presented by median and interquartile range (25th, 75th percentile) and compared by the Mann-Whitney U-test. Categorical variables are described by frequency and percentage. The cumulative recurrence rate of VTE was estimated by the KaplanMeier method. Differences between groups were computed using log-rank tests and adjusted for multiple comparisons to a control group with Dunnett's method. Because of skewed distribution, antibody levels were logbase-2-transformed. Univariable and multivariable Cox proportional hazard models were used to estimate hazard ratios (HRs). The proportional hazards assumption was assessed by evaluating the correlation of the scaled Schoenfeld residuals with time. The linearity of the effect was investigated using simple thresholding by splitting the data into tertiles as well as by modelling the antibody levels using restricted cubic splines. Software tools R 3.2.4 (http://www.R-project.org) and SAS software, Version 9.4 for Windows (SAS Institute Inc. 2014, Cary, NC, USA) were used.
Results and discussion
IgM antibody levels to OxLDL and PC were 20. Table 1) . The cumulative probability of recurrence after 5 years in patients with OxLDL-IgM levels > 28.3 RLU/100 ms (highest tertile) was 13.5% (95% CI, 8.4-18.3%), compared to 20.8% (95% CI, 14.9-26.3%) in the lowest tertile and 19.2% (95% CI, 13.4-24.6%) in the middle tertile (Fig. 1, Panel A) . For PC-IgM the respective (Fig. 1,  Panel B ). These observations indicate that higher IgM antibody levels protect against VTE, which is consistent with data from a prospective population-based survey showing IgM antibodies to predict a lower rate of arterial disease [8] . Innate immune responses may, therefore, play a role in VTE. The association between IgM antibody levels against OxLDL and its PC-epitope and a lower thrombotic risk strengthens the robustness of our findings. IgG antibody levels to PC were 11.7 RLU/100 ms (7.0, 20.89), did not correlate with age (r s = 0.12) or body mass index (r s = 0.03), and were comparable between patients with and without recurrence (10.4 [6.6, 17.7] vs. 11.84 [7.1, 21.7 ] RLU/100 ms, P = 0.11; HR 0.92 [95% CI, 0.80-1.04; P = 0.17] for each doubling of IgG levels). Similar results were seen for IgG antibodies to OxLDL (data not shown). These findings contrast with data from the Bruneck study, where IgG levels were associated with a higher risk of arterial disease [8] , and suggest that IgG antibodies are less relevant for VTE development.
The mechanisms by which IgM antibodies protect from vascular disease are not fully defined. The effects may partly be explained by their ability to neutralize and clear OSE on OxLDL, thereby blocking proinflammatory and prothrombotic properties [16] . Moreover, OSE as targets of natural IgM antibodies are generated by extensive oxidative stress in virtually all cells and are thus present also on other lipids or proteins. For example, extracellular vesicles (EV), which are shed from dying or activated cells including platelets and monocytes, are procoagulant and contribute to thrombotic disease. They may carry OSE on their surface that are recognized by IgM antibodies, resulting in their clearance and dampening of their prothrombotic properties [17] . Future studies will focus on identifying potential mechanisms by which OSE-specific IgM may modulate VTE recurrence.
Our study has strengths and limitations. We prospectively followed a large, well-defined patient cohort at high risk of VTE, but did not study healthy subjects. Natural antibodies were measured once after discontinuation of anticoagulation and not in samples obtained at later time-points. We found an association between levels of IgM antibodies and the risk of VTE recurrence but cannot comment on the role of these antibodies in the risk of an incident event. In this study we set out to prove a concept rather than to identify new clinical diagnostic or prognostic markers. We used OxLDL that contain many different OSE as a model antigen. In addition to PC, IgM antibodies with specificity for other OSE, such as malondialdehyde or mimotopes thereof, have been described [15] . Characterization of IgM antibodies against other OSE may provide further insights into potential mechanisms of their protective effect [18, 19] .
Our findings may have clinical implications. OxLDL alter endothelial cell function by promoting expression of adhesion molecules, enhancing prothrombinase and protein C inhibitor activity, and up-regulating tissue factor Fig. 1 . Kaplan-Meier estimates on the cumulative probability of recurrent venous thromboembolism according to tertiles of IgM antibody levels to oxidized low-density lipoproteins (OxLDL) (Panel A) and phosphocholine (PC) (Panel B). Log-rank-test-based P-values: OxLDL-IgM, low vs. high tertile P = 0.04 (Dunnett corrected 0.07), middle vs. high P = 0.93 (Dunnett corrected 0.99), low and middle combined vs. high tertile P = 0.02; PC-IgM, low vs. high tertile P < 0.01 (Dunnett corrected < 0.01), middle vs. high P = 0.48 (Dunnett corrected 0.70), low and middle combined vs. high tertile P < 0.01. expression and activity [20] . OxLDL also induce platelet activation via CD36, a scavenger receptor expressed on platelets [21] . These prothrombotic properties of OxLDL can be blocked by specific antibodies. For example, the murine OxLDL-specific IgM antibody T15/E06 specific for PC, inhibits their ability to stimulate IL-6 production [22] . OSE are also present on apoptotic cells and blebs, and T15/E06 IgM inhibits the ability of these cells to promote monocyte adhesion by endothelial cells [23, 24] . Thus, natural IgM could modulate the risk of thrombosis also by recognizing cellular debris that shares the same OSE on its surfaces. Indeed, this concept is supported by our previous finding that EV are bound by OSE-specific IgM that inhibits EV-induced IL-8 secretion by monocytes [17] .
In summary, we provide proof of concept that levels of OSE-specific natural IgM antibodies are inversely related to the risk of VTE. The mechanisms by which humoral innate immunity modulates the predisposition to VTE need to be further elucidated. 
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